Hydrogels have emerged as promising tools for targeted drug delivery in cancer therapy, offering high biocompatibility, efficient drug encapsulation, and tunable physico-chemical properties. Doxorubicin (DOX), a widely used chemotherapy drug, faces challenges of drug resistance in tumor cells, necessitating innovative delivery systems to maximize its anticancer effects. Natural-based hydrogels like chitosan, alginate, and gelatin, as well as nanocomposite-enhanced hydrogels, have shown promise in delivering DOX for effective tumor suppression. These hydrogels can co-deliver DOX with other drugs or genes to enhance drug sensitivity, enabling polychemotherapy and synergistic cancer suppression. Incorporating nanoparticles into hydrogel structures can further improve the sustained release of DOX, enhancing its intracellular uptake and cytotoxicity.
To address the complexity of tumor biology and the limitations of current chemotherapeutics, researchers have turned to nanobiotechnology and hydrogel-based systems for combating cancer drug resistance. Nanoparticles play a versatile role in delivering chemotherapeutics along with nucleic acids, siRNA, or miRNA to enhance tumor suppression. Stimuli-responsive hydrogels, such as pH-, redox-, and thermo-sensitive platforms, offer precise control over DOX release at tumor sites, improving cancer treatment outcomes. By leveraging the unique properties of hydrogels, researchers aim to overcome drug resistance, enhance drug bioavailability, and minimize side effects in cancer patients.
Hydrogels, 3D polymeric networks, are being harnessed for efficient drug delivery, with a focus on improving the targeted release of DOX in cancer treatment. These platforms can co-deliver DOX with genes or other drugs, enhancing their synergistic anticancer effects. By utilizing natural polymers and synthetic strategies, hydrogels offer versatile ways to tailor drug release profiles and improve therapeutic outcomes. From co-delivering DOX and cisplatin to developing stimuli-responsive hydrogels for precision drug release, the potential of hydrogel-based systems in cancer therapy is vast.
Co-delivery strategies involving hydrogels have shown promise in enhancing the efficacy of DOX in cancer treatment. By encapsulating DOX with natural products, synthetic complexes, or genes, hydrogels can significantly improve drug bioavailability, tumor targeting, and treatment outcomes. The development of advanced hydrogel platforms with improved drug loading, sequential release capabilities, and tailored physico-chemical properties holds great potential for overcoming drug resistance and improving cancer therapy. Future research should focus on refining hydrogel formulations, exploring novel polymer combinations, and optimizing co-delivery strategies to further enhance the therapeutic potential of DOX in cancer treatment.
Key Takeaways:
– Hydrogel-based platforms offer a promising approach for targeted drug delivery in cancer therapy, enhancing the efficacy of chemotherapy drugs like DOX.
– Combining DOX delivery with genes, natural products, or synthetic complexes using hydrogels shows potential in overcoming drug resistance and improving treatment outcomes.
– Stimuli-responsive hydrogels provide precise control over drug release at tumor sites, minimizing side effects and enhancing therapeutic effects.
– Future research should focus on refining hydrogel formulations, exploring novel polymer combinations, and optimizing co-delivery strategies to maximize the potential of DOX in cancer treatment.
Tags: nanobiotechnology, gene therapy, tissue engineering, lyophilization, chromatography, drug delivery, immunotherapy
Read more on pmc.ncbi.nlm.nih.gov